PRG 241220 45.00C (PRG241220C45000) Stock Options, News & Quotes

0.56
-3.44-86.00%

15min DelayClose Dec 13 16:00 ET

0.56High0.56Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

EricLeaw

Jul 11 07:41

Moomoo AI

Feb 24 07:26

The market's expectations for PROG Holdings were not met, given the contrast between EPS growth and share price decline. The company's future performance is uncertain, urging investors to consider other factors, including risks and financials, before deciding.

Earnings Growth of 2.3% Over 5 Years Hasn't Been Enough to Translate Into Positive Returns for PROG Holdings (NYSE:PRG) Shareholders

Moomoo AI

Jan 2 05:58

The company's P/E ratio reflects limited expected future growth, leading investors to pay a reduced amount for the stock. Unless PROG Holdings improves its earnings outlook, the company's share price is likely to remain at current levels.

Why Investors Shouldn't Be Surprised By PROG Holdings, Inc.'s (NYSE:PRG) Low P/E

Analysts Notebook

Jun 17, 2022 06:11

Columns Top upgrades and downgrades on 6/17: RBLX, AXP, CVS, GRAB and more

Upgrades
• $American Express (AXP.US)$ : Baird Upgrades to Outperform from Neutral - PT $175
• $The AZEK (AZEK.US)$ : BofA Securities Upgrades to Buy from Neutral
• $Capital One Financial (COF.US)$ : Baird Upgrades to Outperform from Neutral - PT $145
• $Fifth Third Bancorp (FITB.US)$ : Baird Upgrades to Outperform from Neutral - PT $44
• $M&T Bank (MTB.US)$ : Baird Upgrades to Outperform from Neutral - PT $200 (from $175)
• $NextEra Energy Partners LP (NEP.US)$ : RBC Cap...

Moomoo Breakfast US

Mar 31, 2022 07:53

Columns Today's pre-market stock movers: CLVS, PATH, DARE and more

Gainers:
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...